SIZE XSSIZE SMSIZE MDSIZE LG

Best of 2018 - Targeting FLT3: an update in the management of FLT3-mutated AML

    • List Price: $35.00
    • Member Price: $25.00
Speaker: Amanda Seddon, PharmD BCOP BCPS

Product Details:

In April 2017, the U.S. Food and Drug Administration approved the first tyrosine kinase inhibitor for the treatment of patients diagnosed with AML. The approval of midostaurin marks the beginning of targeted therapy development for this difficult-to-treat disease. Three other FLT3 inhibitors are cu...

Show More
There are not any reviews for this product.
Contains 0 items
Subtotal: $0.00